Current trends in management of hepatitis B virus reactivation in the biologic therapy era

Hepatitis B virus (HBV) reactivation represents an emerging cause of liver disease in patients undergoing treatment with biologic agents. In particular, the risk of HBV reactivation is heightened by the use monoclonal antibodies, such as rituximab (anti-CD20) and alemtuzumab (anti-CD52) that cause p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Mastroianni, Claudio M, Lichtner, Miriam, Citton, Rita, Borgo, Cosmo Del, Rago, Angela, Martini, Helene, Cimino, Giuseppe, Vullo, Vincenzo
Formato: Artigo
Idioma:Inglês
Publicado em: Baishideng Publishing Group Co., Limited 2011
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3198017/
https://ncbi.nlm.nih.gov/pubmed/22025876
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v17.i34.3881
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados